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HIV, CARDIOVASCULAR DISEASE, ANTI-RETROVIRAL RESISTANCE: THE 
ISSUE WITH PROTEASE INHIBITORS AND A NEED FOR ALTERNATIVES 
MARION GILLCRIST 
ABSTRACT 
 Today, it is estimated that 35 million people are living with human 
immunodeficiency virus (HIV). Since its initial discovery in 1981, researchers and 
medical providers have worked endless hours to understand the pathology, transmission, 
and medical management of HIV. In the early days of HIV, life expectancy after 
diagnosis was 10 years. However, after the development of zidovudine (AZT) in 1987, 
life expectancy of HIV patients began to slowly increase, albeit still lower than that of the 
general population. The development of AZT opened the door for more antiretroviral 
drugs and more drug classes. Now, patients undergo a triple drug regimen to manage 
HIV. These patients are able to maintain viral suppression and are no longer experiencing 
opportunistic infection or other AIDS-related conditions. While HIV is medically 
managed, this is a chronic condition and to-date, not cured. As opposed to opportunistic 
infections and other AIDS-related conditions, patients are succumbing to non-AIDs 
related conditions such as renal, neurological, bone disorders, and liver complications. 
The leading non-AIDs related condition is cardiovascular disease (CVD). Even with viral 
suppression, HIV infection itself contributes to the pathology and development of 
atherosclerosis and CVD. It is clear that chronic immune activation, HIV proteins, and 
dyslipidemia appear to be key factors in CVD development. Since the life expectancy of 
HIV patients has increased, physicians are now seeing an older generation of HIV 
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patients. Medical providers are shifting focus toward understanding the long-term effects 
of not just HIV, but antiretroviral therapy (ART) as well. It appears that drug interactions 
and long-term toxicity augment CVD development. Protease inhibitors (PIs), compared 
to other ART drug classes, appear to increase the risk of atherosclerosis, especially 
through dyslipidemia. Due to management of HIV being life-long, compliance is difficult 
because of high pill burden, drug-drug interactions, and drug side effects. This can result 
in drug failure leading HIV patients to switch to second-line ART regimens. PIs are a 
common component of second-line ART regimens. Compared to other ART drugs, PIs 
have a high genetic barrier to resistance. However, PIs have a low bioavailability 
requiring high dosage and/or boosting with ritonavir (RTV). Lopinavir (LPV) boosted 
with RTV (LPV/r) is a favorable PI as it is used in a combination pill and is the most cost 
effective. However, multiple studies have shown LPV/r correlates more to CVD 
compared to other PIs.  Patients on LPV/r exhibit an increased intima-medial thickening, 
a hallmark characteristic of atherosclerosis and an increased risk for myocardial 
infarction. Unfortunately, researchers are greatly conflicted as to why this is and in 
general why PIs increase the risk of CVD. Future medical treatment for HIV is complex 
and requires long-term medical management. In recent years, integrase inhibitors (IIs) 
have exhibited promise to provide better lipid profiles while maintaining viral 
suppression. However, as this drug class is relatively new and expensive, the financial 
burden on HIV patients is high. The next step toward addressing the global health issue 
of HIV is understanding the exact mechanism of how PIs contribute to CVD. This will 
not only increase the life expectancy of HIV patients, but reduce drug toxicity, non-AIDS 
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related conditions, and increase adherence and viral suppression. It is clear that future 
research must be focused on understanding the role PIs have in CVD development. 
Physicians are seeing an older generation of HIV patients, and a vast majority are on 
second-line regimens. By understanding this relationship, researchers could design 
alternative drugs to manage CVD risk, by modifying current PIs or designing entirely 
new drugs.   
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 Since the first case of HIV in 1981 in the Morbidity and Mortality Report by the 
Center for Disease Control (CDC), there has been a great deal of progress in 
understanding not only the pathology of human immunodeficiency virus (HIV), but 
medical care and management as well. However, despite these medical advances HIV 
still poses a major global health problem. Today, it is estimated that 35 million people are 
living with HIV (Hemelaar, 2013; Ntusi et al, 2016; Wing, 2017; De Cock et al, 2012). 
Initially, HIV was an acute infection characterized as a progressive decline of a patient’s 
immune system until the development of acquired immunodeficiency syndrome (AIDS). 
In the early days of HIV, patients typically had 10 years before HIV seroconverted to 
AIDS. Afterwards, due to a compromised immune system, opportunistic infections and 
neoplasms often occurred, and resulted in death 1-2 years after AIDS diagnosis (Klatt, 
2019; Hutchinson, 2001; Wilks et al 2008; Wing, 2017; Lifson et al, 1992). The epidemic 
of HIV began with panic and uncertainty. Despite the reports that HIV was transmitted 
through blood and sexual intercourse, many were still fearful and mistrusting. Many HIV 
patients faced stigma, discrimination, isolation and social stress which adversely affected 
their already grim medical diagnosis (St. Lawrence et al, 1990; Herek et al, 1988; Bayer, 
1983). In many cases, physicians refused to treat HIV-positive patients (Gillon, 1987; 
Walters, 1988; Kelly et al, 1987). Despite this, many researchers and medical 
professionals worked tirelessly to understand this unknown infection and how to combat 
it. In the Background subsection (pages 4 – 7) of the HIV section (pages 4 – 22) in this 
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thesis, we will explore the history and discovery of this retrovirus by Dr. Robert Gallo 
and Dr. Luc Montagnier (Gallo et al, 1984; Barré-Sinoussi et al, 1983; Vahlne, 2009).  
 
 In 1987, zidovudine [Retrovir; AZT] became the first antiretroviral drug on the 
market after a clinical trial definitively found a decrease in opportunistic infection and 
mortality in AZT treatment compared to placebo. Soon after, more antiretroviral drugs 
began to be made with the first drug class nucleoside reverse transcriptase inhibitors 
(NRTIs) hitting the market (Fischl et al, 1987; Flexner, 2019). By 1996, there was a 
marked decline in AIDS deaths. It became clear that initiation of antiretroviral therapy 
(ART) began to prolong survival of patients with HIV/AIDS (Fleming et al, 2000; CDC, 
1997; Hogg et al, 1997; Hogg et al, 1998; Detels et al, 1998; Wing, 2017). The 
mechanism of action of these drugs will be explained in the Medical Management 
subsection (pages 15 – 22) of the HIV section (pages 4 – 22) (See figure 1). Now, life 
expectancy of HIV patients has increased dramatically, though it is still lower than that of 
the general population (Siddiqi et al, 2016; Wandeler et al, 2016; Nakagawa et al, 2013; 
Marcus et al, 2016; Samji el al, 2013). For these patients, early diagnosis, high CD4+ 
nadir, and high compliance to ART is critical in increasing the life expectancy 
(Nakagawa et al, 2012; May et al, 2014; Johnson et al, 2013; Rodger et al, 2013; Samji et 
al, 2013). 
 
 As opposed to AIDS-related conditions, HIV patients are succumbing to non-
AIDS related conditions such as renal, neurological, bone disorders, hepatic and 
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cardiovascular complications. One of the leading causes of mortality in HIV patients is 
cardiovascular disease (CVD) (Non et al, 2017; Hsu and Sereti, 2016; Anand et al, 2018; 
Kearns et al, 2017; Nakagawa et al, 2013; Ntusi et al, 2016).  In the early days of HIV, 
patients experienced cardiac complications (due to HIV or early ART drugs) that did not 
contribute to their mortality. These cardiac complications were commonly pericardial 
effusions, cardiomyopathy, or structural alterations in cardiac architectures (Hsue, 2019; 
Taelman et al, 1990; Blanchard et al, 1991; Heidenreich et al, 1995; Cohen et al, 1986). 
During this time, physicians were focused on treating HIV as an acute and short-term 
condition due to the development of AIDS and AIDS-related conditions. Now, due to the 
advances of ART, HIV is a chronic condition, and medical providers are seeing older 
patients with HIV. This has created a dramatic shift in medical management from treating 
acute, opportunistic infections, to chronic non-AIDS related conditions, in particular 
CVD and atherosclerosis. 
 
 In the Cardiovascular Disease and HIV section (pages 25 - 38) of this thesis, we 
will explain how HIV infection contributes to the acceleration of atherosclerosis and 
CVD. These mechanisms have long been established and are due to chronic 
inflammation/immune activation, microbial translocation, HIV proteins, and 
dyslipidemia. We will elaborate on how HIV exacerbates these factors, leading to an 
increased risk of CVD (Sokoya et al, 2017; Hsu and Sereti, 2016; Haverich and Boyle et 
al, 2019; Chavez and Pan, 2019; Theron et al, 2017; Hsue, 2019). By understanding how 
CVD and HIV are related, we are able to further delve into how exactly ART influences 
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CVD in the section Protease Inhibitors, Cardiovascular Disease, and HIV (pages 38 – 
49). Compared to other drug classes, protease inhibitors (PI) are low cost and have a high 
genetic barrier to resistance. Drugs with a high genetic barrier require a larger number of 
mutations to cause therapeutic inefficacy compared to drugs with a low genetic barrier. 
Genetic resistance is critical to treatment as this determines the efficacy of a drug. Due to 
this, PIs are an ideal class for HIV treatment. However, studies have shown that PIs in 
particular have increased the risk of CVD (Lorenz et al, 2008; Calza et al, 2009; 
Lipshultz et al, 2012; Chawla et al, 2018; Luber, 2005). This thesis aims to gather and 
investigate the current understanding and relationship of CVD and PIs. By understanding 
the current literature, this will provide guidance for where future research is currently 
going and where it should go in order to reduce CVD risk in the HIV population. In 
addition, this thesis aims to provide current and future therapy alternatives in practice, in 
particular integrase inhibitors (IIs) in order to address the aging HIV population. 
 
HUMAN IMMUNODEFICIENCY VIRUS 
 
Background 
 The first case of HIV in the United States was reported in 1981 in the Morbidity 
and Mortality Weekly Report by the Center for Disease Control (CDC). In Los Angeles, 
five young, gender and sexually diverse men were treated at three different hospitals for 
Pneumocystis carinii pneumonia (PCP). None of the patients had prior contact with each 
other, nor shared sexual partners. Physicians were puzzled at this because PCP is only 
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found in immunosuppressed patients (CDC, 1981). In the next few months, more 
previously healthy gender and sexually diverse men began to suffer from, not only PCP, 
but also Kaposi’s sarcoma (KS). However, this cohort of men had sexual contact with 
other patients with PCP or KS. In some of these patients, symptoms developed over a 
year or longer after initial contact. Physicians suspected some sort of sexually transmitted 
disease, yet at the time there were no known viruses or bacteria that caused 
immunodeficiency (CDC, 1982).  
 
 Critical research that led to the discovery of the HIV virus was the development 
of the protocol to culture human T lymphocytes. In 1976, Dr. Robert Gallo and his 
colleagues were able to grow T cells from human bone marrow using medium derived 
from phytohemagglutinin (PHA). They believed there was a factor present in the media 
that allowed lymphocytes to proliferate and be maintained for over a year in vitro 
(Morgan et al, 1976; Ruscetti et al, 1977). Gallo quickly developed protocols to isolate 
this factor, which is now known as T-cell growth factor (TCGF), and improved 
production and isolation of this factor (Mier and Gallo, 1980; Mier and Gallo, 1982). The 
ability to use TCGF on human T lymphocytes allowed Gallo to isolate one of the first 
human retroviruses, human T lymphocyte virus type 1 (HTLV1) and the subsequent 
related virus HTLV type 2 (HTLV2) (Poiesz et al, 1980; Poiesz et al, 1981). Using the 
techniques created by Gallo, Dr. Luc Montagnier isolated the HIV virus in 1983. 
However, in their paper, he and his colleagues termed this virus lymphadenopathy 
associated virus (LAV). The patient was suffering from lymphadenopathy, which many 
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believed to be a precursor for acquired immunodeficiency syndrome (AIDS) (Vahlne, 
2009; Barré-Sinoussi et al, 1983).  
 
 In 1984, Dr. Gallo published a paper regarding HIV, describing this virus as 
HLTV-III. Samples from 48 patients either presenting with AIDS or pre-AIDS were 
taken. What made this study unique was that the virus was detected in one of the samples 
from an otherwise healthy, gender and sexually diverse male. However, 6 months after 
the tests, the patient developed AIDS. This study began to present strong evidence that 
this virus was a potential causative agent for AIDS (Gallo et al, 1984). Gallo reinforced 
this idea in his second paper by titering antibodies from patients with AIDS. Patients with 
advanced AIDS exhibited lower levels of antibodies compared to patients who were 
newly diagnosed or exhibited pre-AIDS. This suggested that HTLV-III caused T cell 
death, leading to a compromised immune system. (Sarngadharan et al, 1984). His final 
two papers published in 1984, “Detection, Isolation, and Continuous Production of 
Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS” and 
“Serological Analysis of a Subgroup of Human T-Lymphotropic Retroviruses (HTLV-III) 
Associated with AIDS,” allowed for further characterization of the virus (structural 
characteristics) and described a protocol to detect the virus in serum samples through 
Western blot (Popovic et al, 1984; Schüpbach et al, 1984; Vahlne, 2009). As the years 
went on, numerous articles were published about LAV, HLTV-III, and AIDS-associated 
retrovirus (ARV) and their relationship to AIDS and other diseases (Hutchinson, 2001). 
By 1986, in order to create cohesiveness in the science community, the modern term 
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human immunodeficiency virus (HIV) was announced by the International Committee on 
Taxonomy of Viruses as the causative virus of AIDS (Case, 1986).  
 
Biology and Transmission 
 Human Immunodeficiency Virus (HIV) is part of the family Retroviridae, which 
belongs to the genus Lentivirus. Compared to other retroviruses, those which are part of 
the genus lentivirus are characterized as having a long incubation period between 
exposure and the emergence of clinical symptoms (Klatt, 2019; Weston and Marett, 
2009; Caliendo and Kraft, 2016). Retroviruses, as a whole, are distinguished by their 
ability to reverse transcribe (via reverse transcriptase) their RNA genome into DNA. 
After the RNA is reverse transcribed, the DNA is then integrated into the host genome to 
be replicated using the host’s protein production machinery (Weston and Marett, 2009). 
 
 HIV virus targets immune cells such as CD4+ T helper cells, CD68+ monocytes 
and macrophages of CD4+ lineage, and dendritic cells found in the lymphoid germinal 
centers. After initial entry of the virus, cell destruction occurs through apoptosis or 
pyroptosis (a programmed cell death) via caspase 1. As the immune system is gradually 
destroyed, the development of immune function impairment, constitutional diseases, 
opportunistic infections, neurological complications, and neoplasms can occur (Lucas 
and Nelson, 2015; Hutchinson, 2001). A pre-stage for the development of clinical AIDS 
is a decline in patient CD4+ cell count to 500 cells per cubic millimeter (average CD4+ 
levels vary from 500-1700 cells per cubic millimeter depending on sex at birth and race). 
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However, once a patient’s CD4+ count falls below 200 cells per cubic millimeter and/or 
one of the twenty-five AIDS-indicator conditions (See Table 1) are present, the patient is 
classified, clinically, as having AIDS (Hutchinson, 2001; Klatt, 2019; Wilks et al, 2008; 
Rhodes et al, 2019; Kone et al, 2017; Crampin et al, 2011). 
 
 HIV has numerous modes of fluid transmission/exchange including but not 
limited to sexual contact, blood transfusions/organ donation, and intravenous drug usage 
(Hladik and McElrath, 2008; Shaw and Hunter, 2012; Lucas and Nelson, 2015). Mother 
to child transmission (MTCT) is a common cause of pediatric HIV. Transmission to 
infants can occur in utero, during delivery, and through breast milk (Klatt, 2019; Douglas 
et al, 2017). Initially, pregnant women took AZT monotherapy. However, it is now 
recommended to administer 2 nucleoside reverse transcriptase inhibitors (NRTI) and non-
nucleoside reverse transcriptase inhibitors (NNRTI) or protease inhibitor (PI). However, 
even without ART, transmission of HIV is low (about 40%). With ART adherence, 
MTCT is as low as 2% (Douglas et al, 2017; Chappell and Cohn, 2014; Mark et al, 2012; 
Blanche, 2020). Currently, in utero transmission is not fully understood. However, there 
are many working theories including the protective effects of the placenta, 
chorioamnionitis increasing the risk of transmission, high viral load, and co-infections 
(Blanche, 2020; Arora et al, 2017; Kapembwa et al, 2017; Givens et al, 2018). Infants are 
at a high risk of transmission during labor. Rupture of the amniotic sac exposes the fetus 
to maternal blood and vaginal fluids, especially when viral load is detectable. The fetus 
can aspirate these fluids during labor or while leaving the birth canal and increase the risk 
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of transmission. In addition, placental micro transfusions can occur during labor by 
mixing the maternal and fetal blood. Due to this, it is recommended that HIV postitive 
women undergo cesarean sections (C-section). However, vaginal delivery is possible if 
the viral load of the mother is less than 1000 copies/mL (Mark et al, 2012; Klatt, 2019; 
Douglas et al, 2017; Milligan and Overbaugh, 2014). Breast milk is one of the more 
common modes of transmission. Mothers are recommended not to breastfeed unless there 
are no alternatives. However, there are a large number of infants who are breastfed that 
do not become infected with HIV. It is suggested that although breast milk exposes the 
infant to the virus, it may block viral transmission by innate factors and HIV-1 
antibodies. IgA has been shown to reduce the risk of HIV transmission and IgG 
especially has been shown to neutralize HIV (Shen et al, 2015; Givens et al, 2018). 
Despite this, it is ideal for the mother to maintain a low viral load, as the HIV virus can 
cross the mucosal barrier of the gastrointestinal (GI) tract in the infant. In addition, the 
infant can undergo “post-exposure prophylaxis” (PEP) to reduce the risk of MTCT 
(Blanche, 2020; Chappell and Cohn, 2014; Givens et al, 2018; Klatt, 2019).  However, 
transmission has variant risk for sexual encounters. Studies have shown that penile-
vaginal transmission occurs as high as 1 in 10 exposures compared to penile-anus 
transmissions occurring as high as 1 in 3 exposures. This suggests that the vaginal canal, 
with stratified squamous epithelium, provides a stronger mechanical barrier against the 
HIV virus than the anus, with single columnar epithelium. Anal intercourse has the 
highest per exposure likelihood of infection compared to all other transmission sites 
(Shaw and Hunter, 2012; Klatt, 2019; Gonzalez et al, 2019).  
 
10 
Mechanism and Infection 
 HIV is a one ten-thousandth of a millimeter bilayer sphere with spikes. The spikes 
are comprised of gp120 and gp41 glycoprotein. Inside the bilayer is a matrix protein layer 
with a cone-shaped core (capsid) inside. The capsid contains two strands of RNA (the 
virus’s genetic material), reverse transcriptase, protease, and integrase proteins 
(Hutchinson, 2001, Klatt, 2019). Unlike other retroviruses, HIV has more genes with 
elaborate interactions. It is comprised of long terminal repeats (used as promoters) on 
each side of the 10kb genome. The three main genes are gag, pol, and env. Gag codes for 
the core proteins, structural elements, and is critical in the ability of HIV to migrate out of 
the host cell. Pol, codes for the reverse transcriptase, protease, and integrase, all of which 
are critical for the virus to integrate into the host cell’s DNA. Env, codes for the external 
glycoproteins gp120 and gp41, which are used to bind to target cells. There are also two 
regulatory genes tat and rev. While tat functions as a transcription amplifier of the HIV 
virus, rev processes the transcripts into late phase (after 24 hour) gene expression. 
Finally, there are four additional genes vpu, nef, vif, and vpr. Vpu allows the newly 
formed HIV virus to bud out of an infected cell, while nef is involved in the infectivity of 
the virus (when active, the virus is as high as ten times more infectious compared to when 
the protein is not expressed). As the virions (newly formed viruses) leave the host cell, 
nef is packaged as well. Studies have shown that the lack of nef and vif has led to a less 
efficient proviral DNA creation. However, nef, has shown to have little interaction with 
reverse transcriptase. Finally, vpr facilitates the virus’s genome entrance into the nucleus 
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by binding to the nuclear pore (Klatt, 2019; Levy, 1993; Hutchinson, 2001; Fauci, 1988; 
Hope and Trono 2000). 
 
 All retroviruses need a host cell in order to replicate, as they do not contain DNA. 
After exposure to the virus, the HIV surface protein gp120 has a high affinity for CD4+ 
receptor molecules. These molecules include, but are not limited to, CD4+ T helper cells 
and monocytes. However, after binding to the CD4+ receptor, gp120 must bind to G-
protein coupled chemokine receptors CXCR4 and/or CCR5 (CCR5 is the predominant 
receptor). This binding is critical, as it causes a conformational change in gp41, which 
allows for internalization of the virus into the host cell. Without gp41, the virus cannot 
fuse into the host cell (Hutchinson, 2001; Klatt, 2019). Once the virus is internalized, the 
RNA is reverse transcribed into proviral DNA by reverse transcriptase. The integrase 
protein attaches to the proviral DNA and binds it to the host DNA. The proviral DNA is 
then transcribed and translated by the host cell’s machinery (Klatt, 2019; Fauci, 1988). 
The newly translated HIV proteins are cleaved by HIV’s protease, and the new viral 
RNA gathers together. Using the host cell’s membrane, the virus particle will form and 
bud off (Weston and Marett, 2009; Klatt, 2019).  
 
Classes and Genetic Diversity 
 HIV-1 has been shown to arise from a cross-species transmission of primates to 
humans. The primate lentivirus version of HIV, simian immunodeficiency virus (SIV), 
has been shown to originate from chimpanzees and gorillas. Independent cross-species 
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transmission has led to four HIV-1 virus lineages: M, N, O, and P groups (Klatt, 2019). 
Like many lentiviruses, there is a high amount of diversity and divergence. However, 
each virus has eight genes in common: gag, pol, env, tat, erv, vif, vpr, and nef. Nucleic 
acid sequencing and antibody testing of these genes, specifically the pol and env regions, 
revealed the chimpanzee Pan troglodytes troglodyes (SIVcpz) to be the origin of HIV-1 
groups M and N (Sauter and Kirchhoff, 2019; Keele et al, 2006). Groups O and P are 
closely related to the lowland gorillas, Gorilla gorilla (SIVgor). However, studies have 
revealed that SIVgor strains are part of the SIVcpz clade, an observation that suggests 
that SIV could have potentially crossed from chimpanzees to gorillas and then to humans 
(Keele et al 2006, D’arc et al 2015; Van Heuverswyn et al, 2006; Abecasis and 
Vandamme, 2018). HIV-1 group M (HIVM) is the most prevalent and is responsible for 
the global pandemic of HIV/AIDS. It is currently postulated that HIVM cross-species 
transmission occurred in the early 20th century due to exotic monkeys being kept as pets 
or exposure to infected primate blood from hunting and butchering of chimpanzees for 
“bush meat”' in Southern Cameroon. During this time, HIVM further divided into genetic 
subtypes A, B, C, D, F, G, H, J, and K. (Keele et al 2006; Hemelaar, 2013, Klatt, 2019). 
HIVM traveled south from Southern Cameroon via the Sangha River (or other tributaries) 
to the Congo River and Kinshasa (previously known as Leopoldville, Zaire) in Congo. 
From Kinshasa, the global HIVM epidemic started infecting more than 40 million people 
(Abecasis and Vandamme, 2018; Hemelaar, 2013; Keele et al 2006). Unlike HIVM, 
groups N and P are rare and have been found almost exclusively in Cameroon. While 
group O is more prevalent, it has only accounted for infecting 100,000 individuals, 
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mainly in Cameroon, Gabon, Nigeria and other neighboring countries (Klatt, 2019; D’arc 
et al 2015).  
 
 Compared to other viruses, HIV creates numerous mutations due to its high 
recombination rate, high replication rate, and lack of proof-reading proteins. After initial 
exposure, HIV virus has been shown to be homogenous. This suggests that only a few 
viral strains enter. From there, a bottleneck occurs and a rapid multiplication leads to 
genetic diversity. Due to this diversity, subtypes can vary as high as 17%. In HIVM, 
subtype A and F have two sub-subtypes A1/A2 and F1/F2, respectively. HIVM subtypes 
can interact and create a new inter-subtype termed circulating recombinant forms (CRFs) 
or unique recombinant forms (URF). In order for a CRF to be classified as URF, the CRF 
must be sequenced and there must be three or more unlinked individuals. CRFs are found 
in about 20% of HIV-1 infections. Of the current 55 CRFs, the most common ones are 
CRF01_AE and CRF02_AG. These are commonly found in Asia and West Africa 
(Abecasis and Vandamme, 2018; Hemelaar, 2013; Joseph et al, 2015).  
 
 In 1986, HIV-2 was first reported in West Africa and is still commonly found in 
these countries; specifically, Guinea-Bissau, Senegal, Sierra Leone and Mozambique. 
Similar to HIV-1 the virus was transmitted cross-species through bodily fluids. However, 
HIV-2 was found to originate from sooty mangabeys, Cerococebus atys. HIV-2 diverges 
into subgroups A through I with subgroup A and B accounting for the majority of the 
pandemic spread. Patients suffering from HIV-2 have a longer asymptomatic phase, 
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higher CD4+ cell count and a lower viral load leading to a slower progression to AIDS, 
compared to HIV-1. In contrast to HIV-1, HIV-2 is less transmissible, with penile-
vaginal transmission rates five to ten times lower than HIV-1, and maternal-fetal 
transmission as low as 1-2%. This is most likely due to HIV-2 patients having lower viral 
load (De Cock et al, 2012; Klatt, 2019; Visseaux et al, 2016; Ingole et al, 2013) 
 
HIV phases 
 After initial infection, the virus incubates for two to four weeks. During this time, 
the patient is asymptomatic and all blood tests for HIV antibodies and antigens are 
negative, tissue biopies of lymph nodes are the only way to diagnose HIV. However, as 
the HIV virus replicates and the load increases, the patient may experience 
seroconversion illness, characterized as flu-like symptoms such as headache, fever, 
muscle aches, exhaustion, and/or swollen lymph nodes. During this seroconversion, also 
known as the acute phase, the potential for transmission is high due to the high viral load 
(Wilks et al, 2008; Levy, 1993; Lucas and Nelson, 2015). Antibodies are commonly 
detected in the blood 6-18 weeks after initial infection with HIV (Hutchinson, 2001). 
During the acute phase, the viral load will reach a peak, and then it will drop and reach a 
steady “set point”. At this time, viral load will remain steady as the virus transitions from 
the acute to latent phase. This “set point” is influenced by a multitude of factors, such as 
strain of HIV-1, host immune response to HIV, sex assigned at birth (with women 
commonly lower than men, though the rates of progression are similar), and number of 
cells available (Klatt, 2019). During the latency period, the patient is asymptomatic; 
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however, the patient can develop constitutional symptoms such as fever, weight loss, 
fatigue, and/or mild immunodeficiency illnesses ranging from herpes simplex to bacterial 
infections. Without antiretroviral therapy (ART), a typical patient will progress to AIDS 
in about 10 years with about 10% of non-ART HIV patients (termed rapid progression 
patients) developing AIDS in 2-5 years. The set point strongly correlates with the 
development of AIDS, with higher set points progressing to AIDS more rapidly as 
compared to lower set points. During the latent phase, the viral load will progressively 
increase while the number of CD4+ cells will consistently decrease. This steady CD4+ 
cell decrease severely weakens the immune system and leads to AIDS (CD4+ cell count 
of 200 cells per cubic millimeter or less). Due to a compromised immune system, 
opportunistic infections and neoplasms often occur (Klatt, 2019; Hutchinson, 2001; 
Wilks et al 2008).  
 
Medical Management 
 Depending on the exposure of the virus, there are three different forms of HIV 
medical management: pre-exposure, post-exposure (24-72 hours), and high active 
antiretroviral therapy (HAART). Pre-exposure prophylaxis (PrEP) is administered to 
individuals with a higher than average risk of HIV. These individuals include, but are not 
limited to, men who have sex with men, intravenous drug users, sex workers, persons 
who live in areas with a high HIV presence, and people in a relationship with an HIV 
positive person. There are currently two modes of PrEP intervention approved for use: 
topical tenofovir (TFV) (NRTI) or a daily pill combination of tenofovir disoproxil 
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fumarate [Viread; TDF] and emtricitabine [Emtriva; FTC] (2 NRTIs) in either a fixed 
dose combination or individual pills. Truvada is the fixed dose combination of FTC and 
TDF. While both have been shown to reduce the transmission of HIV, adherence is 
difficult due to misconceptions about personal risk and also daily dosages (Nicol et al, 
2013, Eakle et al 2018; Donnell et al, 2017; Heendeniya and Bogoch, 2019). Current 
PrEP research is focused on reducing the pill burden of PrEP, which will also lower 
costs, and finding other modes of administration such as long acting injection or vaginal 
ring. While TDF/FTC (either as individual pills or Truvada) taken non-daily or as part of 
an event-driven dosing protocol has shown potential, more research is needed before this 
strategy becomes part of the PrEP protocol (Anderson, 2016; Mitchell et al, 2018; Nicol 
et al 2013). Post-exposure prophylaxis is a three-drug combination for 28 days for both 
non-occupational and occupational exposure. It is recommended that the exposed patients 
receive two NRTIs and an integrase inhibitor (II) or PI. The preferred three-drug 
combination is (TDF/FTC) with raltegravir [Isentress; RAL]. If RAL cannot be used, due 
to cost, availability, or tolerance, dolutegravir [Tivicay; DTG] is a suggested alternative. 
Pregnant women or women of childbearing age are not recommended to take dolutegravir 
due to an increased risk of neural tube defects (Dominguez et al, 2016; Krakower et al, 
2015; Heendeniya and Bogoch, 2019).  
 
 For HIV positive patients, NRTI AZT became the first antiretroviral treatment in 
1987. Initially, ART was a monotherapy. However, in 1995, studies found that a three-
drug combination was the best therapy for HIV/AIDS management, and it became the 
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standard of care in 1997. This triple drug combination was termed HAART, however, 
this term is now used colloquially and interchangeably with ART. Now, there are dozens 
of antiretroviral drugs available which can be used in triple drug combination. 
Antiretroviral therapy is divided into five categories: NRTIs, NNRTIs, PIs, IIs, and entry 
inhibitors (EIs), also known as fusion inhibitors or CCR5 antagonists (See Table 2) 
(Wilks et al, 2008; Morse and Nanzigu, 2015: Klatt, 2019; Flexner, 2019). 
 
 NRTIs inhibit reverse transcriptase from converting viral RNA into proviral DNA 
(See Figure 1). After being integrated into the building DNA strand, NRTIs, lacking a 3’ 
hydroxy group, prevent phosphodiester linkage for elongation. This drug prevents the 
virus’s genetic material from integrating into the host cell’s DNA by looking structurally 
similar to nitrogenous bases. Current HAART guidelines prescribe two NRTIs and a third 
drug from another class. Within the NRTIs class, there are two sub-classes: nucleoside 
and nucleotide inhibitors. Abacavir [Ziagen; ABC], FTC, lamivudine [Epivir; 3TC], and 
AZT are all categorized as nucleoside inhibitors. TDF is the only nucleotide inhibitor. 
Despite the different sub-classes, all NRTIs act via the same mechanism and are 
administered as either single-dose or in fixed-dose combination (Klatt, 2019; Moss et al, 
2015; Wilks et al 2008). While didanosine [Videx; ddI] and stavudine [Zerit; d4T], are 
additional available NRTIs, they are rarely prescribed due to their renal and liver toxicity 




 NNRTIs act on reverse transcriptase by binding to the catalytic site of the enzyme 
(See Figure 1). This causes a conformational change and reduces the catalytic ability of 
the enzyme. This can be through direct or non-competitive binding to the 
enzyme. Current NNRTIs are nevirapine [Viramune; NVP], efavirenz [Sustiva; EFV], 
etravirine [Intelence; ETR], rilpivirine [Edurant; RPV], and doravirine [Pifeltro; DOR]. 
While delavirdine [Rescriptor; DLV] was available and had little safety concerns, the 
manufacturer discontinued production of this product in October of 2018 (Flexner, 2019; 
Moss et al, 2015 Klatt, 2019; Ernst, 2017). Unlike other drugs, the entire class can be 
rendered inactive due to a mutation in the enzyme that replaces a leucine with a tyrosine 
(Y188L). This alteration disrupts binding energy of the NNRTI to RT enzyme (Feng et 
al, 2015; Basson et al, 2015; Lai et al, 2016).  
 
 PIs act on HIV protease by binding to the active site (See Figure 1). By 
preventing protease function, the virus’s polyproteins are no longer processed; 
specifically, the gag and pol genes. These genes produce important components of the 
virus such as the core and the matrix. If a virus lacks these structures and buds from a 
host cell, the new virus will become immature and noninfectious. Currently, available PIs 
are atazanavir [Reyataz; ATV], darunavir [Prezista; DRV], fosamprenavir [Lexiva/Telzir; 
FPV], indinavir [Crixivan; IDV], nelfinavir [Viracept; NFV], saquinavir [Invirase; SQV], 
and tipranavir [Aptivus; TPV]. Due to PIs low bioavailability, many PIs must be given in 
high dosages and are commonly administered with a pharmacokinetic enhancer, ritonavir 
[Norvir; RTV]. Lopinavir [Kaletra; LPV] is the only drug that is administered as a fixed-
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dose combination with RTV. A major side effect of PIs are their inhibition of the 
cytochrome P450 enzyme system, which can lead to drug interactions. However, 
compared to other HIV therapy drugs, PIs have a low likelihood of patients developing 
drug resistance (Flexner, 2019; Klatt 2019; Sumner et al, 2015).  
 
 IIs work by inhibiting strand transfer of viral DNA into the host’s genome (See 
Figure 1). After forming metal coordination with metals such as magnesium (Mg2+) or 
manganese (Mn2+), the integrase enzyme becomes active and can integrate the viral DNA 
into the host’s DNA. Many IIs are derivatives of diketo acids that can bind to metals 
within the integrase enzyme. This metal binding deactivates the enzyme and prevents the 
integration of the viral DNA. IIs RAL and DTG are the only drugs of this class that are 
given alone. The other two IIs are given as the brand name fixed-dose multi-class 
combination pills Stribild and Biktarvy. Stribild contains the II elvitegravir (EVG), which 
must be taken with cobicistat (COBI) to boost the effect and prevent rapid drug 
metabolism. Biktarvy contains bictegravir (BIC). Unfortunately, at this time the absence 
of generic form of these drugs creates a high financial burden on HIV patients (Flexner, 
2019; Nanzigu and Kasujja, 2015) 
 
 EIs prevent entry of the HIV virus into the host cell (See Figure 1). Currently, 
there are three drugs that prevent entry into the cell. Enfuvirtide [Fuzeon; ENF] works by 
preventing the HIV virus from fusing with the host cell. After binding to the CD4 
receptor and CXCR4/CCR5 on the host cell, gp41 on the HIV virus will promote fusion 
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of the viral envelope with the host cell membrane. ENF works to prevent this by targeting 
the sequences on gp41 called heptad repeats 1 and 2 (HR1/HR2). Currently, this drug can 
only be given subcutaneously. Maravoiroc [Selzentry; MVC] works by preventing HIV 
binding to the host cell. As opposed to ENF, MVC targets human host cells and binds to 
CCR5 or CXCR4. Currently, MVC is undergoing clinical trials as a potential drug for 
PrEP individuals. Ibalizumab [Trogarzo; IBA] is a monoclonal antibody for the CD4 
receptor. Like MVC, IBA binds to the human host cells and prevents gp120 from binding 
to the CD4 receptor (Flexner, 2019; Klatt, 2019; Sawyer et al, 2015). 
 
 Fixed-dose combination pills can be prescribed as single or multi-class drug 
combinations. NRTIs drug combinations are the most common of the fixed-dose 
combination drugs. The current drug combinations are 3TC/AZT [Combivir], 3TC/TDF 
[Cimduo/Temixys], ABC/3TC [Epizicom], and a triple combination drug, 
ABC/AZT/3TC [Trizivir]. Descovy is a less toxic form of TDF/FTC [Truvada] which 
uses tenofovir alafenamide [TAF] instead of TDF. A major concern for TDF is renal 
toxicity and bone mineral loss (De Clercq, 2010; Dionne, 2019; Moss et al, 2015; Sax et 
al, 2014; Fletcher; 2018). Many PIs must be given with a pharmacokinetic booster [RTV 
or COBI]. ATV/COBI [Evotaz], DRV/COBI [Prezcobix] and LPV/RTV [Kalerta] are the 
current treatments to decrease pill burden (Dionne, 2019). In addition, there are now 
many multi-class fixed dose combinations. NRTI/NNRTIs are the largest group of fixed-
dose multi-class drug combinations followed by NRTI/INSTI, NNRTI/INSTI, and 
NRTI/PI combination. There are currently five drugs available: TDF/FTC/EFV [Atripla], 
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TDF/FTC/RPV [Complera], 3TC/TDF/DOR [Delstrigo], TAF/FTC/RPV [Odefsey], and 
TDF/3TC/EFV [Symfi] (De Clercq, 2010; Dionne, 2019). NRTI/INSTI drugs consist of 
TAF/FTC/BIC [Biktarvy], 3TC/DTG [Dovato], 3TC/ABC/DTG [Triumeq] and two 
drugs that are given with enhancers FTC/TAF/EVG/COBI [Genvoya] and 
TDF/FTC/EVG/COBI [Stribild] (Dionne, 2019; Flexner, 2019). Finally, the 
NNRTI/INSTI drug is RPV/DTG [Juluca] and the NRTI/PI drug is 
TAF/FTC/DRV/COBI [Symtuza] (Dionne, 2019). 
 
 After initial diagnosis, HIV-positive patients begin first-line ART. Current 
strategy for first-line therapy is giving 2 NRTIs and a third drug from another class. The 
third drug is commonly from the class of integrase or protease inhibitors. However, due 
to PIs need to be administered in high doses and with a booster, IIs are highly preferred. 
In addition, IIs are typically well tolerated. However, other factors must be considered 
when prescribing ARTs such as the drug-drug interactions, specific needs, comorbidities 
(diabetes, renal, hepatitis B), adherence, pregnancy, and tolerability to side effects (Kelly 
et al 2019; Klatt, 2019; Moss et al, 2015). In addition, many patients that are beginning 
first-line ART have taken antiretroviral medications previously either as PrEP, PEP, pre-
natally to prevent MTCT, or have discontinued an ART regmine voluntarily. This further 
complicates ART strategies as pre-exposure can lead to more drug resistant strands and 
first-line therapy failure (Gupta et al, 2018; Inzaule et al, 2018). Currently the US 
Department of Health and Human Services (DHHS) and World Health Organization 
(WHO) recommend the following first-line ART drugs: DTG/TDF/FTC, EVG/TDF/FTC, 
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or RAF/TDF/FTC. TDF can be either TAF or TDF (Kelly et al, 2019; Klatt, 2019; WHO, 
2019). However, due to the high mutation rate of the HIV virus, drug resistance is 
common. This can lead to second and even third line ART. Treatment failure is accessed 
in three ways: clinical, virological, and immunological. Clinical failure is accessed by the 
appearance of opportunistic infections, weight loss, or emergence of other AIDS-related 
conditions. Immunological failure is characterized as a decline in CD4+ cell count, 
whereas virological failure is defined as the inability to decrease the RNA viral load to 
<1000 copies/mL. Failure can be due to a multitude of factors, including prior exposure 
to ART, drug toxicity, drug side effects, advanced HIV staging, primary infection by a 
drug resistant strain and levels of baseline clinical factors (low CD4+ cell count or high 
pretreatment viral load). Low BMI has also been shown to be a predictor of treatment 
failure. However, this is seen more in low-income countries due to low nutritional status. 
Since ART must be taken for a lifetime, many patients experience treatment fatigue 
leading to lower drug adherence (Ayalew et al, 2016; Agezew et al, 2019; Ahmed et al, 
2019; Ayele et al, 2018). Second line therapy recommends two NRTIs with a PI boosted 
with RTV (PI/r). PIs commonly used are LPV or ATV. However, if NRTI resistance is 
found, LPV/r with II RAL has been shown to be an alternative (Claassen et al, 2019; 




 Atherosclerosis is a key factor in the development of CVD. This condition affects 
large and medium sized arteries, and it is characterized by an accumulation of lipids in 
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blood vessel walls and a build-up of plaque. Genetic and lifestyle habits/environment 
influences the development and progression of atherosclerosis. As lipids accumulate 
within arteries, a plaque is formed. This can lead to altered blood flow, which will 
prevent oxygen supply to various body parts and organs. If the plaque breaks and blocks 
a downstream vessel, blood flow can become obstructed and can lead to stroke, 
myocardial infarction (MI), or cardiac death (Chistiakov et al, 2018; Mayer and Binder, 
2019; Tabas et al, 2015). 
 
Pathology 
 Atherosclerosis begins with endothelial dysfunction, which can be triggered by 
oxidative stress, inflammation, and abnormal blood flow patterns. Endothelium 
dysfunction is associated with an expression of receptors for monocytes and other 
leukocytes. Cholesterol, low-density lipoprotein (LDL), and other lipids begin to 
accumulate under the endothelium into the intima layer of the artery by transcellular and 
paracellular transport (Mundi et al, 2017; Zhang et al, 2018; Chistiakov et al, 2018; 
Mayer and Binder, 2019; Tabas et al, 2015). Fatty streaks begin to form. LDLs become 
oxidized and can further stimulate inflammation and the recruitment of immune 
leukocytes (this oxidation mechanism is explained in the Dyslipidemia subsection (pages 
34 – 38) of the Cardiovascular Disease and HIV section (pages 25 – 38). Macrophages 
begin to migrate into the intima and bind to oxidized LDL molecules via scavenger 
receptors. As they engulf more LDL molecules, they become foam cells. The fatty core 
begins to accumulate with foam cells, smooth muscle cells that move from the media into 
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the intima layer of the blood vessel, and cellular debris. The extracellular matrix 
surrounding the core is lost. As the lesion grows, cells begin to die and make a necrotic 
core. Smooth muscle cells lay down collagen and other matrix components. This fatty 
buildup is now called a fibroatheroma: a necrotic core, fat buildup, and thin fibrous cap. 
However, when this cap breaks off, the plaque ruptures. Thrombosis often occurs at the 
rupture site and arterial blood flow can be blocked. Depending on the location, this can 
lead to stroke, MI, or renal complications. In other cases, the plaque can break off and 
become lodged further downstream causing an arterial embolism in other locations like 
the lungs (pulmonary embolism) or the legs (deep vein thrombosis). However, it is also 
possible that the thrombus may not be severe and can be incorporated into the plaque. 
This slowly promotes stenosis of the arterial lumen. Due to the altered blood flow, the 
body may compensate by creating collateral vessels to maintain blood flow (Chistiakov et 
al, 2018; Mayer and Binder, 2019; Tabas et al, 2015). In some cases, this plaque buildup 
can calcify and harden the arteries. Calcification of the arteries is not fully understood, 
but a few mechanisms have been proposed: apoptosis of smooth muscle cells and 
macrophages, loss of mineralization inhibitors, differentiation of vascular smooth muscle 
cells into osteoblasts, and/or the release of circulating matrix vesicles. While in many 
cases, calcification has been shown to increase stability of plaques, it is a major causal 





 While this process begins at childhood and will progress until old age, there are 
many factors that can accelerate atherosclerosis development. These risk factors are 
divided into genetic and environmental markers. There are many classic genetic risk 
factors such as family history of heart disease, sex assigned at birth, and age. Men have a 
higher risk of heart disease compared to women. Heart disease and atherosclerosis risk 
increase dramatically as people age with men’s risk increasing after the age of forty-five 
and women, the age of fifty-five. There are many comorbidities that increase the risk for 
heart disease such as chronic kidney disease. Dialysis patients have a higher risk of CVD 
compared to the general population. Obesity encompasses many risk factors not limited 
to dyslipidemia, hypertension, and diabetes. Those who have a high amount of intra-
abdominal fat have a higher likelihood of CVD. Lifestyle and environmental decisions 
such as smoking, sedentary lifestyle, and unhealthy diet (however studies have shown 
that consumption of cholesterol only contributes a small amount to atherosclerosis) have 
all shown to independently contribute to CVD development. Finally, high levels of 
cholesterol and LDL, and a low level of high density lipoproteins (HDLs) have been 
shown to be major risk factors in atherosclerosis (Haverich and Boyle, 2019; Mayer and 
Binder, 2019; Mahmoud et al, 2014). 
 
CARDIOVASCULAR DISEASE AND HIV 
 
 Due to medical advances and understanding of HIV and ART, life expectancy of 
HIV patients has increased dramatically. Patients are no longer suffering from 
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opportunistic infections, but rather age-related diseases such as cancer, bone disorders 
(especially osteoporosis), neurocognitive disorders, kidney disease, chronic obstructive 
pulmonary disease, diabetes, and CVD (Guaraldi, 2016; Hileman and Funderburg, 2017). 
Compared to the general population, HIV patients are over two times more likely to 
suffer from a MI or other CVD-related complications. It is one of the leading causes of 
non-AIDS related deaths in the HIV population (Alvaro et al, 2019; Glesby and Myerson, 
2019; Maggi et al, 2017; Lambert et al, 2016; Triant et al, 2018). Due to the complicated 
medical profile of these patients, it is difficult to ascertain the sole cause of CVD in HIV 
patients. It is suspected that it is due to a combination of ART, traditional lifestyle 
factors, genetics, and HIV inflammation and immunosuppression (See Figure 2) (Triant 
and Grinspoon, 2017). 
 
Immune Activation and Inflammation 
 Strategic Timing of Antiretroviral Treatment (START) and Strategies for 
Management of Antiretroviral Therapy (SMART) were two critical clinical trials that 
provided insight into the relationship between inflammation, HIV, and CVD. START, 
was a multi continental randomized study that investigated the risk and benefit of 
beginning ART immediately after diagnosis (asymptomatic HIV+ patients) or deferring 
beginning ART until CD4+ cell count was 350 cells per cubic millimeter. Prior to this 
study, physicians typically deferred ART until a patient's CD4+ cell count dropped below 
a certain level. This threshold varied and remained inconsistent among the medical 
community. Many physicians chose to defer ART due to the long-term complications and 
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toxicity of ART drugs. The START study found that starting ART immediately after 
diagnosis, regardless of CD4+ cell count, was superior to deferring treatment. By 
beginning ART immediately after diagnosis, a patient's risk of not only AID-related 
conditions, but non-AIDS related conditions went down (START study group, 2015). 
SMART, was a multi continental randomized study that investigated the benefit of 
episodic use of ART (a cycle of initiating, or reinitiating ART once a patient’s CD4+ cell 
count hit less than 250 cells per cubic millimeter or when symptoms of HIV infection 
surfaced, such as opportunistic infections, and then stopping ART once a patient’s CD4+ 
cell count reached 350 cells per cubic millimeter) or continuous use of ART. The 
SMART study found that continuous use was beneficial and superior for HIV patients 
compared to episodic use. Contrary to what was expected, the results showed that 
patients on episodic use had higher rates of cardiovascular, renal, or hepatic disease. It 
was initially believed that these rates would be lower among episodic usage of ART by 
minimizing drug toxicities associated with ART (SMART study group, 2006). These 
studies were pivotal as they began to suggest an interplay between low CD4+ cell count, 
elevated HIV viremia, and non-AIDS related conditions, especially CVD.  
 
 It is well understood that inflammation plays a critical role in the development of 
CVD. Inflammation induces endothelial dysfunction which, in turn, further heightens the 
inflammation response by recruiting monocytes, releasing pro-thrombotic and pro-
inflammatory cytokines, and increasing expression of adhesion molecules [intercellular 
adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)] (Kearns et al, 
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2017, Nou et al, 2016). Compared to the general population, HIV patients exhibit higher 
levels of inflammatory biomarkers such as interleukin-6 (IL-6) (systemic inflammation 
marker), C-reactive protein (CRP) (systemic inflammation marker), D-dimer (coagulation 
and fibrinolytic pathway activation marker), tumor necrosis factor-alpha (TNF-A) 
(inflammation marker) and adhesion molecules ICAM and VCAM (endothelial activation 
markers) (Chavez and Pan, 2019; Hsu and Sereti, 2016; Nou et al, 2016; Hileman and 
Funderburg, 2017; Bahrami et al, 2016; Maggi et al, 2017). These inflammatory markers, 
especially IL-6, CRP, and D-dimer, have been associated with an increased risk of 
atherosclerosis development and CVD (Haverich and Boyle, 2019; Duprez et al, 2012; 
Maggi et al, 2017). These elevated levels persist despite ART and suggests that immunity 
isn’t fully restored, and immune dysfunction persists despite medication. For HIV 
patients, there are a multitude of reasons that create chronic inflammation such as 
microbial translocation, chronic immune activation, and/or co-infections, (Bahrami et al, 
2016; Longenecker et al, 2016; Hsue, 2019; Hileman and Funderburg, 2017; Sereti et al, 
2017).   
 
 Within the gut is gut-associated lymphoid tissue (GALT), where a large amount 
of CD4+ T-cells reside. During the early stages of HIV infection, GALT is a major target 
for infection. This results in massive inflammation and alteration of gene expression, 
which can be alleviated, but not restored with ART. Tight junction protein expression 
goes down and epithelial apoptosis occurs resulting in increased GI permeability or 
‘leaky gut’. This allows for intestinal microbial products to enter the circulation (termed 
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microbial translocation) and to bind to pattern recognition receptors on monocytes, 
macrophages, and dendritic cells creating more inflammation (Hsu and Sereti, 2016; Nou 
et al, 2016; Hsue, 2019).  
 
 Immune activation is critical for the host’s defense against foreign particles. 
However, this becomes a dangerous cycle within HIV patients as they are chronically 
infected by foreign particles. Despite ART, inflammation levels are never fully restored 
in HIV patients. This suggests that despite viral suppression, there are potentially 
constant circulating low levels of HIV viremia in tissues of the body (Hileman and 
Funderburg, 2017). CD4+, monocytes and other cells are produced when the host’s 
immune system detects HIV viremia within the body. In addition, regulatory T cells 
(Tregs), regulators of immune activation, increase with increasing viremia levels. 
However, Tregs inhibit B and T cell proliferation. This is mainly through transforming 
growth factor-beta 1 (TGF-B1), which is responsible for many functions within the body. 
Two major functions are immune regulation and fibrosis. While TGF-B1 has been shown 
to suppress proliferation of B and T cells, this cytokine can be stimulatory or inhibitory 
for monocytes and macrophages, depending on the microenvironment (Theron et al, 
2017; Frangogiannis, 2012; Hanna and Frangogiannis, 2019). Immune activation 
propagates infection as the virus is provided targets for infection and replication. As the 
CD4+ cells are lost, the immune system responds by increasing activation and 
proliferation of the CD4+ cells. Tregs inhibit CD8+ and CD4+ levels, allowing for levels 
of HIV viremia to rise furthering immune dysregulation and exhaustion (Sokoya et al, 
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2017; Penaloza-MacMaster et al, 2014; Kleinman et al 2018, McLane et al, 2019; 
Hasenkrug et al, 2018).  
 
 Native T-cells (the precursors to CD4+, CD8+ and other T-cells) are produced in 
two ways: the thymus or proliferation of existing cells. While the thymus involutes 
naturally with age, there are various diseases that can accelerate this process. The HIV 
virus attacks the thymus leading to disruption and/or apoptosis of naive T-cells. Due to 
this, the body relies heavily on the proliferation of existing naive T-cells (Sokoya et al, 
2017; Ansari and Liu, 2017). As T-cells travel through the blood and return to the lymph 
node, they can be exposed to an antigen-presenting cell. During this time, T-cells become 
activated and begin to create a response. The fibroblastic reticular cell, located in the T 
cell zone of the lymph node, is responsible for organizing/guiding T-cells, facilitating 
antigen-presentation to T-cells, and preventing autoimmunity. During HIV infection, 
these cells become damaged due to chronic inflammation, especially due to elevated 
levels of TGF-B1. This can lead to fibrosis of the lymph nodes, resulting in T-cell 
apoptosis, furthering immunosuppression (Brown and Turley, 2016; Theron et al, 2017; 
Zeng et al, 2012). T-cells that are made from existing T cells (in particular CD4+ cells) 
express higher levels of CCR5 rendering these cells more susceptible to the HIV virus. 
Chronic CD4+ cell activation creates a vicious cycle within an HIV patient, eventually 
leading to premature immune aging, immunosenescence and immune exhaustion 
(Paiardini and Muller-Trutwin, 2013; Sokoya et al, 2017). T-cells begin to terminally 
differentiate and express CD57, a senescence marker, due to the high turnover and cell 
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proliferation. These cells have a shortened telomere length, decreased proliferation 
ability, and decreased half-life. Eventually, this cycle will lead to a continual loss of 
CD4+ cells. This not only increases the likelihood of opportunistic infections (further 
promoting inflammation), but CVD. Recent studies have found that low CD4+ cell count 
correlated with CVD, a finding that reinforces the connection between immune 
activation, inflammation and CVD (Maggi et al, 2017; Triant and Grinspoon, 2017; 
Sokoya et al, 2017; Longeneck et al, 2016; Hsu and Sereti, 2016). This strengthens the 
implications of the SMART and START studies that there is a relationship between 
immune activation and CVD.  Patients with episodic use and patients with deferred 
treatment (i.e., patients with a low CD4 cell count and/or elevated levels of viral RNA) 
end up having an increased likelihood of CVD related deaths (SMART study group, 
2006; START study group, 2015).  
 
 Activation of the innate immune system, specifically monocytes, plays an 
important role in the development of atherosclerosis. Many monocyte activation markers, 
specifically CD14 and CD163, have been associated with increased intimal-medial 
thickening (IMT) and arterial inflammation, especially within HIV patients (Hileman and 
Funderburg, 2017; Hsu and Sereti, 2016; Triant and Grinspoon, 2017; Subramanian et al, 
2012; Chavez and Pan, 2019; Longenecker et al, 2016; Nou et al, 2016). IMT has been 
shown to be a strong indicator for evaluating risk of CVD and the development of 




 Monocyte activator CD163 has been strongly correlated with non-calcified 
plaques (Bahrami et al, 2016; Kearns et al, 2017; Subramanian et al, 2012; Fitch et al, 
2013). This atherosclerotic morphology is unique and distinct for HIV patients. These 
plaques are more susceptible to rupture and thrombosis, which could be the likely reason 
for an increased risk of CVD in HIV patients (Ballocca et al, 2017; Bernelli et al, 2020). 
 
HIV proteins 
 While HIV causes many downstream effects due to the host’s immune response, 
HIV proteins themselves have been shown to alter cellular mechanisms. Multiple HIV 
proteins lead to endothelial dysfunction on different levels. Tat and Gp120 have been 
shown to increase expression of adhesion molecules, reactive oxygen species (ROS) 
production, and endothelial permeability by altering tight junction proteins (Mezoh and 
Crowther, 2019; Anand et al, 2018; Yu et al, 2020). Nef, vpr and gp120 have been shown 
to directly stimulate monocyte activation, promoting inflammation (Younas et al, 2016; 
Sokoya et al, 2017) 
 
 Hijman et al found that gp120 and tat increase endothelial cell senescence. As 
endothelial cell function becomes altered, an increased release of pro-inflammatory 
markers such as IL-6 begins to occur. Senescent cells have been shown to decrease 
expression of nitric oxide (NO), further promoting the development of atherosclerosis 
(Hijmans et al, 2018). Production of NO, a vasodilator, is critical for vascular 
homeostasis, and alteration of this can lead to endothelial dysfunction. Changes in 
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bioavailability of NO can either be due to an increase in NO inhibitors and/or a decrease 
in NO production. ROS can influence NO bioavailability by reacting with NO, creating 
peroxynitrite, or modifying NO producing enzymes (Marincowitz et al, 2019). HIV 
proteins, nef and gp120, have been shown to exacerbate this process by downregulating 
NO production directly (Nou et al, 2016; Mezoh and Crowther, 2019). Whereas, gp120 
and tat can decrease NO production indirectly by increasing ROS. Gp120 has been 
shown to increase production of ROS intermediates such as hydrogen peroxide (H2O2) 
(Yu et al, 2020). Vpr increases ROS production by downregulating glutathione (GSH) 
levels and increasing H2O2 production (Ivanov et al, 2016; Porter and Sutliff, 2012). 
NADPH oxidases are a family located on membranes, commonly the mitochondria. This 
family of oxidases create superoxide anions (Ivanov et al, 2016). Tat has been shown to 
downregulate GSH levels and to activate NADPH oxidase (Anand et al, 2018; Yu et al, 
2020; Ivanov et al, 2016; Porter and Sutliff, 2012). Nef increases expression of adhesion 
molecules and has been shown to inhibit cholesterol efflux by downregulating ATP-
binding cassette transporter (ABCA1) on macrophages. This transporter is critical, as 
without this, cholesterol will accumulate within macrophages and lead to a higher 
likelihood of foam cell development and inflammation (Yu et al, 2020; Non et al, 2017; 
Kearns et al, 2017; Yvan-Charvet et al, 2010). Low et al found that patients with a nef-
deficient strain of HIV-1 exhibit a higher likelihood of developing HDL particles 
compared to patients with a nef-present strain of HIV-1. This study is consistent and 
further reinforces the current understanding that nef has been shown to alter HDL 




 Dyslipidemia is characterized by any abnormal serum lipid levels [lipoproteins 
(HDL, VLDL, LDL), total cholesterol (TC), and/or triglycerides (TAG)].  For evaluating 
CVD risk, there is a major focus on HDL and LDL. Elevated levels of LDL specifically 
have been shown to be associated with atherosclerosis and the development of CVD. 
While elevated TAGs have also been shown to be associated with CVD, the relationship 
is disputed. However, it is suspected that elevated TAG levels are associated with other 
CVD risks such as hypertension, insulin resistance, and low HDL levels (Myerson et al, 
2015; Myerson, 2019; Nou et al, 2016; Duncan et al, 2019). 
 
 HIV infection and ART, individually and in conjunction, create varying changes 
in lipid concentrations. After HIV seroconversion, prior to ART, patients exhibit lower 
levels of LDL, TC, and HDL (Non et al, 2017; Riddler et al, 2007; Waters and Hsue, 
2019). However, after initiation of ART, LDL, TC, and TAGs levels increase while HDL 
levels remain low (Funderburg and Mehta, 2016; Non et al, 2017; Bowman and 
Funderburg, 2019). These levels vary depending on the ART drug classes. However, PIs 
have been found to alter lipid levels to the greatest degree (Waters and Hsue, 2019; 
Bowman and Funderburg, 2019; Funderburg and Mehta, 2016).  
 
 Duprez et al examined and evaluated CVD events in patients during the SMART 
clinical trial. This was one of the first reports studying the lipid profiles of HIV patients, 
and it found a causal link for CVD risk. Investigators showed that inflammation appears 
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to play a role in altering HDL levels. Inflammatory markers (D-dimer and IL-6) were 
found to be inversely correlated with HDL levels. This suggests the protective anti-
atherosclerotic function of HDL is altered, by some mechanism, by HIV. This loss of 
function most likely contributes to CVD and atherosclerosis development (Duprez et al, 
2009). 
 
 A hallmark characteristic of atherosclerosis is oxidized LDL particle (oxLDL) 
accumulation within the intima. Endothelial dysfunction allows for LDL entry into the 
intimal layer of the blood vessel paracellularly. However, LDL can enter the intima by 
binding to an LDL receptor on endothelial cells, Scavenger receptor B1, activing 
receptor-like kinase 1, and caveolae mediated transcytosis (Mundi et al, 2017; Zhang et 
al, 2018). Once in the intima, LDL particles become oxidized. Inflammation, specifically 
oxidative stress, modifies these lipids and further exacerbates inflammation by activating 
more monocytes. Adhesion molecules (ICAM and VCAM), especially in HIV patients, 
are upregulated and allow for leukocyte transmigration, especially monocytes (Grome, et 
al, 2017; Yu et al, 2020; Hileman and Funderburg, 2017; Zidar et al, 2015). Reactive 
oxygen species (ROS) are normal byproducts of many metabolic reactions within the 
cell. However, ROS are very reactive free radicals, and, if left unchecked, ROS will react 
with biological molecules such as DNA and lipids. This can lead to cellular damage. Due 
to this, ROS is regulated and neutralized by many antioxidants and redox proteins 
especially GSH and thioredoxin (See Figure 3). H2O2, which can react with iron cations 
via the Fenton Reaction or Haber-Weiss cycle, produces ROS (See Figure 4). Once LDL 
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molecules react with ROS, they become oxidized (oxLDL). OxLDL begins to 
accumulate, increasing expression of adhesion molecules (ICAM and VCAM) for 
transmigration of monocytes. Once in the intima, monocytes differentiate into 
macrophages and begin to engulf oxLDL particles. Eventually, as the lipids accumulate 
in the macrophages, they will convert into foam cells and develop fibrous plaques in the 
intima (Ivanov et al, 2016; Couret and Chang, 2016; Gracia et al, 2017; Mayer and 
Binder, 2019).  
 
 For HIV patients, this process becomes exacerbated.  Compared to the general 
population, HIV patients exhibit higher levels of oxidative stress (an imbalance of ROS 
production and neutralization) and H2O2 production. Antioxidants, GSH and TRX, have 
shown to be at diminished levels, which can further increase oxidative stress. Multiple 
mechanisms such as chronic inflammation (especially TGF-B1), HIV proteins, and low 
CD4+ count have shown to either increase ROS production or reduce antioxidant levels 
(GSH and TRX). As oxLDL levels increase, monocyte activation becomes increased as 
well (Ivanov et al, 2016; Couret and Chang, 2016; Hileman and Funderburg, 2017; 
Gracia et al, 2017; Rose et al, 2006; Non et al, 2017; Maisa et al, 2015; Theron et al, 
2017; Morris et al, 2012). Both Kelesidis and Zidar, separately found that elevated 
oxidized lipids can drive monocyte activation and enhance the pro-atherosclerotic 
process. Zidar found that after exposing monocytes to oxLDL, there are increased levels 
of CD14+CD16+ monocytes (inflammatory pro-atherosclerotic monocyte that release 
cytokines and ROS) and CD14+, a monocyte activation marker. Kelesidis found a 
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positive correlation with both oxHDL, oxLDL and inflammatory markers. They 
especially found a strong correlation between oxHDL and monocyte activation marker 
CD163+ (Kelesidis et al, 2016; Zidar et al, 2015; Liang et al, 2017). 
 
 HDL dysfunction, commonly due to oxidation, leads to many pro-inflammatory 
mechanisms and a loss of many cardio protective mechanisms such as reduction of 
monocyte adhesion, endothelial repair, and anti-oxidation. One of HDL’s main functions 
are cholesterol efflux from the tissues to the liver. Macrophages express ABCA1 and 
transport cholesterol to HDL particles. Dysregulation of this mechanism has shown to be 
strongly associated with CVD-related events (Waters and Hsue, 2019; Bowman and 
Funderburg, 2019; Rohatgi et al, 2014). In HIV patients, ABCA1 has shown to be 
impaired (most likely due to inflammation, exposure to microbial products due to “leaky 
gut,” and HIV proteins) and results in cholesterol buildup in macrophages (Non et al, 
2017; Kearns et al, 2017; Funderburg and Mehta, 2016; Liang et al, 2017). 
 
 Dyslipidemia in HIV patients creates a multi-level and multi-step contribution to 
the development of atherosclerosis and CVD-related events. These patients exhibit high 
levels of LDL and low levels of HDL, strong biomarkers of CVD in the general 
population. In conjunction, these patients exhibit increased levels of inflammation which 
plays a key role in the development of atherosclerosis, but also the dysregulation of LDL 
and HDL particles (Duncan et al, 2019; Riddler et al, 2007; Feeney and Mallon et al, 
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2011). It is critical to understand these cellular mechanisms in order to provide therapy 
for HIV patients.  
 
PROTEASE INHIBITORS, CARDIOVASCULAR DISEASE, AND HIV 
 
First-Line and Second-Line Therapy 
 Due to the complexity and chronic nature of HIV, patients need to remain on 
ART their entire life. This makes patient adherence a major challenge for medical 
providers. For HIV patients, treatment failure is common, requiring patients to change to 
second or even third-line ART regimens. Low adherence can be due to a multitude of 
factors not limited to pill burden, long-term toxicity, and side effects. For many drugs, 
multiple pills may be needed multiple times a day or need to be consumed with or 
without food. In addition, social factors such as food insecurity, socioeconomic status, 
long distance traveling to pharmacies, financial difficulties, and stigma influence a 
patient’s adherence to ART (Bukenya et al, 2019; Ayalew et al, 2016; Bezabih et al, 
2019; Ramadhani et al, 2014). Treatment failure is characterized by clinical (new 
opportunistic infections), virological (increasing viral load despite therapy), and 
immunological failure (low CD4+ cell counts). A common reason for virological failure 
is ART resistance, especially to NNRTIs. This transition increases the cost and toxicity 
for patients, but PIs have a low likelihood of inducing resistant strains of the virus 
(Shroufi et al, 2019; Ayalew et al, 2016; Chimbetete et al, 2018; Haile and Berha, 2019). 
After treatment failure, it is critical to switch quickly, as delay in treatment increases the 
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risk of mortality and development of opportunistic infections as well as drug resistance 
and virus transmission (Haile and Berha, 2019; Shroufi et al, 2019).  
 
 Due to the concern of the increasing risks and side effects of ART, the European 
Agency for the Evaluation of Medicinal Products established the Data Collection on 
Adverse Events of Anti-HIV Drugs (DAD) in 1999. The first study, published in 2003, 
collected data from over 23,000 HIV patients in 21 countries over 1999 to 2002. This 
study was one of the first studies to illustrate the risk of CVD, particularly the incidence 
of MI in the wake of ART. In the first four to six years of ART, there is a 26% increase in 
the rate of MI per year. However, it is critical to understand that despite this increase in 
risk, only 6.4% of patients died from MI. AIDS-related conditions were still the leading 
cause of death. This illustrates that the benefits of ART outweigh the increased risk 
(DAD study group, 2003). However, developers of ART have made large strides in 
recent years creating drugs with lower toxicities, side effects and dosages. Despite this, 
CVD is still one of the leading causes of non-AIDS related deaths (Alvaro et al, 2019; 
Glesby and Myerson, 2019; Maggi et al, 2017; Lambert et al, 2016; Triant et al, 2018). 
 
Potential Mechanisms 
 Recent studies have shown ART, independent of HIV pathology and other 
lifestyle risk factors, to be instrumental in the development of atherosclerosis and CVD. 
Compared to other ART drug classes, there has been a major focus on PIs (Lorenz et al, 
2008; Calza et al, 2009; Lipshultz et al, 2012; Chawla et al, 2018). In 2007, the DAD 
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aimed to understand the association of ART and MIs. As before, HIV patients from over 
21 countries were followed from 1999 to 2005. While the incidence and risk of MI 
increased with every year of exposure to ART, the strongest rate of association was with 
PIs. Compared to other ART drug classes, PIs alter a patient’s lipid levels (increasing TC, 
LDL, and other lipids), increasing the likelihood of CVD. While this most likely wasn't 
the only mechanism, PI-induced dyslipidemia appeared to be a risk factor (Friis-Moller et 
al, 2007). Since then, there have been many trials to understand and ascertain which PI 
treatments create ‘high risk’ for CVD and why. While it is not fully understood how 
PI/r increases the likelihood of CVD related events, there are many molecular 
mechanisms that are suspected (Friis-Moller et al, 2007; Alvi et al, 2018; Ryom et al, 
2018; Maggi et al, 2007).  
 
 Currently, the only molecular mechanism for CVD that has been strongly 
established is PI-associated dyslipidemia (See Figure 5) (Riddler et al, 2008; Ofotokun et 
al, 2015; Flint et al, 2009; Feeney and Mallon, 2011). LPV/r in particular, has been 
shown to increase the likelihood of a patient developing dyslipidemia (elevated TC, non-
HDL lipids, and TAGs). In some cases, LDL levels were severely elevated and were in 
need of immediate intervention (Dai et al, 2019; Mills et al, 2009; Molina et al, 2010; 
Matoga et al, 2017; Limsreng et al, 2016; Gleason et al, 2016; Shafran et al, 2005). While 
dyslipidemia is a risk factor for CVD, it is suspicious to believe that PI-associated 
dyslipidemia is the only reason for PIs’ increased risk of CVD and many researchers 
agree (Lang et al, 2010; Worm et al, 2010). Researchers know that ART independently 
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contributes to CVD, with PIs posing one of the highest risk factors (Lorenz et al, 2008; 
Calza et al, 2009; Lipshultz et al, 2012; Chawla et al, 2018). Therefore, there must be 
some other underlying mechanism that contributes to CVD development. 
 
 As seen above in the Cardiovascular Disease section (pages 22 – 25), it is well 
known that inflammation plays a pivotal role in atherosclerosis development. While HIV 
increases this inflammation, as explained in the Cardiovascular and HIV section (pages 
25 – 38), it appears that PIs have been shown to increase IL-6, an inflammatory marker. 
Borges et al found patients on PIs to have elevated IL-6, and there have been multiple 
studies in vitro correlating PIs (by Bogachus and Turcotte; Chen et al; Zhou et al) with 
increased IL-6 levels, (Borges et al, 2015, Bogachus and Turcotte, 2011; Chen et al, 
2009; Zhou et al, 2007).  While the mechanism is unclear, multiple studies have found 
PIs to increase the risk and development of atherosclerosis (Lai et al, 2003; Lekakis et al, 
2008; Dressman et al, 2003; Thomas et al, 2007). Vascular evidence supports these 
claims as HIV patients on PIs exhibit a higher likelihood of IMT and carotid lesions, a 
hallmark of atherosclerosis (Sun et al, 2015; Maggi et al, 2000; Hsue et al, 2004; 
Seminari et al, 2002; Lekakis et al, 2008). While some studies have argued PIs induce 
endothelial dysfunction and monocyte activation, this is unclear and is in need of further 
research (Stein et al, 2001; De Gaetano et al, 2003; Baliga et al, 2004; Torres et al, 2014). 
 
 LPV/r has been of particular interest for contributing to CVD. There have been 
multiple conflicting studies that argue that it increases inflammation and immune 
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activation, contributing to CVD (Squillace et al, 2018). Patients on LPV/r have been 
shown to exhibit increased IMT, a clinical marker for atherosclerosis (Gleason et al, 
2015; Gleason et al, 2016; Longenecker et al, 2016; Hsue, 2019; Martin et al, 2006). In 
addition, LPV/r decreased NO production, induced oxidative stress, endothelial cell 
senescence and inflammation, and increased adhesion molecule expression (Auclair et al, 
2014; Lagathu et al, 2007). However, Wang et al, found that RTV alone increased NO 
and ROS production, whereas LPV made no alterations in NO production (Wang et al, 
2009). However, Auclair et al, Lagathu et al, and Wang et al, studies were on HIV-
negative cells.  
 
 It is currently suspected that RTV is the main cause of PI influence on CVD. 
Compared to other drugs, PIs have a low bioavailability due to low aqueous solubility, 
low intestinal permeability, and rapid metabolism. In order to reduce the high pill burden 
and drug toxicity, and increase drug effectiveness, RTV is commonly prescribed as a 
pharmacokinetic booster because it inhibits intestinal and hepatic cytochrome P450. 
While this increases the half-life and availability of PIs, inhibition of cytochrome P450 
can increase the half-life and decrease clearance of other drugs potentially causing drug-
drug interactions. It is currently unclear how RTV inhibits cytochrome P450, but there 
are many suspected mechanisms such as irreversible binding. In addition, RTV inhibits 
P-glycoprotein reducing active transport of PIs out of cells (Subbaiah et al, 2017; Tseng 




 Myocardial fibrosis (MF) can occur after a MI or from other fibrosis forming 
conditions. While this is a self-healing mechanism due to injury or disease, this can lead 
to impaired heart function. Abnormal regulation and production of fibrosis can occur 
because of chronic inflammation (as seen with HIV) and other mechanisms such as 
oxidative stress and platelet activation (Hinderer and Schenke-Layland, 2019; Hsue and 
Tawakol, 2016; Laurence et al, 2018; Ntusi et al, 2016; Meyer et al, 2012; Laurence et al, 
2017).  
 
 Chronic inflammation markers in HIV patients correlate with elevated levels of 
TGF-B1. Despite ART, TGF-B1 levels do not decrease (Maina et al, 2016; Osuji et al, 
2018; Ahamed, et al, 2016; Malherbe et al, 2014; Nordell et al, 2014; Theron et al, 2017). 
Fibroblasts have been shown to be stimulated by TGF-B1, especially after a MI, and this 
factor has been shown to be a ‘master switch’ for inhibiting inflammation post-MI 
(Theron et al, 2017; Frangogiannis, 2012; Hanna and Frangogiannis, 2019). RTV also 
appears to elevate TGF-B1 levels by activating platelets (Ahamed et al, 2016; Karim et 
al, 2019; Laurence et al, 2018). This potential mechanism has been supported in mouse 
models correlating RTV with TGF-B1 upregulation, inflammation, and MF (Laurence et 
al, 2017, Zhang et al, 2014; Chen et al, 2009, Loelius et al, 2018; Cipriani et al, 2013).  
 
 As explained in the Cardiovascular and HIV section (pages 25 – 38), chronic 
inflammation appears to be due to chronic immune activation, in particular microbial 
translocation. In vivo mouse models and in vitro studies, RTV was shown to disrupt the 
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intestinal epithelial barrier through apoptosis and can contribute to systemic chronic 
inflammation (Wu et al, 2010; Zhou et al, 2011; Renga et al, 2014).  In vitro RTV was 
found to increase platelet aggregation, activation, and release of the pro-inflammatory 
mediator prostaglandin E2. Elevated levels of prostaglandin E2 is suspected of leading to 
platelet hyper responsiveness. This platelet dysregulation can contribute to chronic 
inflammation in HIV patients. Additionally, RTV has been shown to induce endothelial 
dysfunction by downregulating NO and inducing oxidative stress (Loelius et al, 2018; Fu 
et al, 2005; Conklin et al, 2004). A small study was conducted by Shafran et al that 
investigated RTV in 20 HIV-negative patients for 2 weeks. The results found that RTV 
increased TC, LDL, and TAG, and decreased HDL levels alone, while LPV/r increased 
HDL levels, but the total/HDL ratio was not altered (Shafran et al, 2005). While these 
were HIV-negative patients, this small amount of evidence does point to a potential 
mechanism especially since RTV is administered with all PIs. However, further studies 
are difficult to do as it is unethical for HIV-negative patients to remain on PIs long-term.  
 
 There is a large amount of conflicting data and a lack of evidence in 
understanding the role inflammation plays in PI-associated CVD. There have been 
multiple articles arguing that PIs don’t increase inflammatory biomarkers, atherosclerosis 
development or CVD (Arenas-Pinto et al, 2015; Estébanez et al, 2014; Henry et al, 2004; 
Piconi et al, 2013; Depairon et al, 2001; Bozzette et al, 2003). In particular, McComsey et 
al argued that there was no increase in a major inflammatory marker, IL-6, when patients 
were exposed to PIs (McComsey et al, 2012). In addition, PIs have not been shown to 
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increase the likelihood of IMT, a hallmark characteristic of atherosclerosis and CVD 
(Currier et al, 2007; Hulten et al, 2009; Mangili et al, 2006; Depairon et al, 2001; Currier 
et al, 2005; Lebech et al, 2007; Lorenz et al, 2008). Other studies have found that LPV/r 
doesn’t induce endothelial dysfunction or inflammation (Dube et al, 2008; Hattab et al, 
2014; Estébanez et al, 2014). 
 
 Looking at the current research, it appears there was a great deal of focus in 
understanding PI-associated CVD in the late 1990s and early 2000s. Now, there are few 
articles investigating this phenomenon. While it is currently unclear why, this could be 
due to the complexity of HIV, the emergence of more ART drug classes, or a lack of 
understanding of HIV infection itself that needed to be uncovered in more recent years. 
In addition, patients were still suffering from AIDS-related conditions in the late 1990s 
and early 2000s, and, therefore, non-AIDS related conditions may have been somewhat 
of lesser concern for medical providers and researchers.  
 
Alternative Therapies and Management 
 Patients can either switch classes or remain in the PI class. SQV/r, ATV/r, DRV/r 
have not been found to be inferior to LPV/r with respect to viral suppression and have 
improved lipid profiles (Molina et al, 2010; Walmsley et al, 2009; Limsreng et al, 2016; 
Mills et al, 2009; Lai et al, 2003). While these PIs have been suggested as alternatives for 
maintaining viral suppression, it is currently unknown what side effects these other PIs 
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may have. Recently, there have been many studies that found IIs, compared to PIs, to be 
non-inferior and capable of maintaining viral suppression in HIV patients. In fact, they 
could be superior due to reduced pill burden and faster viral suppression (Arribas et al, 
2014; Jacobson and Ogbuagu, 2018; Hidalgo-Tenorio et al, 2019;). In addition, IIs have a 
high genetic barrier to resistance and are well tolerated (Kelly et al, 2019; Oliveira et al, 
2018). 
 
 Multiple studies have shown improved lipid profiles of HIV patients switching 
from PI/r to another drug class, in particular IIs. Gatell et al conducted a study group 
across six European countries and 32 clinical sites. Patients either remained on their PI/r 
therapy (which could be any PI: LPV, SQV, FPV, DRV, or ATV) with two NRTIs, or 
replaced their PI/rs with DTG, an II. They found that viral suppression was successful 
with patients switching to DTG and the lipid profiles of these patients improved. TC, 
TAGs, LDL and non-HDL levels of DTG patients decreased significantly (P<0.001). A 
major finding was the 7.7% reduction of LDL levels, as these lipoproteins are major 
biomarkers for the development of atherosclerosis and CVD (Gatell et al, 2017). Gatell et 
al further investigated if DTG was better when given immediately or with delayed 
administration. The patients that deferred switching to DTG (at the 48-week mark until 
96-week mark) were at a high risk of CVD. They found there was no difference in viral 
suppression, and the improved patient lipid profile suggests that regardless of lipid status, 
DTG can maintain low lipid levels and reduce the risk of CVD (Gatell et al, 2018). Other 
studies have similar findings, and illustrate that switching from PIs to DTG is well 
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tolerated, maintains viral suppression and improves lipid levels (Moron-Lopez et al, 
2018; Aboud et al, 2019; Clotet et al, 2014; Orrell et al, 2017). 
 
 An earlier study by Negredo et al found similar lipid modifications and successful 
viral suppression in patients switching from PI/rs to DTG. While TC, TAG, and HDL 
reduction levels were statistically significant, only TAG reduction levels had a P value 
<0.001. While both of these studies were conducted over 48 weeks, Negredo et al only 
conducted this study in Spain using ABC/3TC as the NRTI backbone. While the drug 
classes themselves are the same, these small biomolecular pathways and mechanics could 
account for the differences in lipid levels between these two studies (Negredo et al, 
2016). These differences cannot take away the significance of Negredo el al and Gatell et 
al’s findings. In both of these studies, lipid profiles of patients improved, and reduced the 
risk of CVD. Other available IIs (RAL and EVG) have yielded similar results in reducing 
TC levels, TC/HDL levels, and other lipid levels (Arribas et al, 2014; Taramasso et al, 
2018; Martínez et al 2010; Martínez et al, 2012; Krikke et al, 2018; Eron et al, 2010; 
Masiá et al, 2012). In addition, after switching from PIs, RAL was found to reduce 
platelet activation in mice and in HIV patients (Tunjungputri et al, 2014; Zhang et al, 
2014). 
 
 Carbon monoxide (CO) has shown to be a promising intervention for fibrosis. At 
low levels, CO can mimic the heme oxygenase-1, an enzyme that protects against 
oxidative stress. It is hypothesized that this could be through its antioxidant properties 
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(mimicking antioxidant nuclear factor erythroid 2-related factor and suppress TGF-B1 
expression) (Ahamed and Laurence, 2017; Zhou et al, 2005; Wang et al, 2008; Ahamed, 
et al, 2016; Laurence et al, 2017). However, CO inhalation is dangerous. Compared to 
oxygen, CO has an over 200-fold higher affinity for hemoglobin. This can lead to 
inhibition of oxygen delivery. Severe acute exposure to CO can make patients critically 
ill and in some cases cause death. Even at low doses, chronic exposure can lead to 
myocardial injury, ischemia, and arrhythmia. Therefore, while there is potential in this 
concept, further work and understanding must occur in order to ascertain the benefits or 
lay the groundwork for more realistic interventions (Ahamed and Laurence, 2017; Rose 
et al, 2017). 
 
 While newer studies have focused on finding a vaccine for HIV, the ability and 
feasibility to design a vaccine, and the complexity of the virus makes this difficult. A 
major issue is the lack of an animal model. While lentiviruses occur in many animal 
species, the mechanism, pathology, and development of HIV is too dissimilar to that in 
humans. While chimpanzees have provided an alternative (HIV came from chimpanzees 
and scientists have infected chimpanzees experimentally), these animals are now 
endangered and can no longer be utilized for research. The high variability of the HIV 
virus and envelope glycoprotein increases the difficulty of developing a potential vaccine, 
as well (Chiodi and Weiss, 2014; Robinson, 2018). After transmission of HIV, the virus 
undergoes a bottle neck effect in which few viral strains enter the host. From there, a 
rapid replication and diversification occurs, leading to high genetic diversity. This same 
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genetic variability allows HIV to avoid neutralizing antibodies (Abecasis and 
Vandamme, 2018; Hemelaar, 2013; Joseph et al, 2015). It is this genetic diversity that 
complicates the ability to make an effective vaccine. In order for a vaccine to work, there 
must be serological memory, a pool of antibodies against an antigen previously 
confronted. While there have been clinical trials investigating the possibility of an HIV 
vaccine, the results have shown the vaccines to be ineffective (See Figure 6). (Chiodi and 
Weiss, 2014; Rerks-Ngarm et al, 2009; Hemelaar, 2013; Hammer et al, 2013; Robinson, 
2018). 
 
 While a clinical trial of RV144 was able to give a small degree of protection 
(31%), it was not significant enough to promote further vaccine development. However, 
this study provided promise and potential for future vaccination research (Chiodi and 
Weiss, 2014; Rerks-Ngarm et al, 2009; Hemelaar, 2013; Hammer et al, 2013; Robinson, 
2018). There are currently multiple clinical trials ongoing and enrolling participants 
(HVTN 121, 124, 128, 702 and 705). This is not including clinical trials close to accrual. 
However, just recently HVTN 702 was discontinued due to ineffectiveness. (Robinson, 




 Due to the complexity of HIV and the medical management of these patients, it 
can be overwhelming for medical providers. Despite this, physicians and researchers 
have come a long way in the last four decades since HIV has emerged. HIV is no longer a 
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death sentence for these patients, but a manageable chronic illness. In the coming years, 
there will be a large population of older HIV patients that previously was not present. 
While there is and has been a major focus on non-AIDS related conditions and 
understanding the development and pathology, it is clear from the research presented in 
this thesis that there is a gap in knowledge. Researchers and medical providers know that 
these conditions exist, but there is little understanding about how they develop and what 
can be done to treat this upcoming population. For HIV patients, CVD is one of the 
leading non-AIDS related causes of death (Alvaro et al, 2019; Glesby and Myerson, 
2019; Maggi et al, 2017; Lambert et al, 2016; Triant et al, 2018). In 2014, the Joint 
United Nations Programme on HIV and AIDS (UNAIDS) presented their 90-90-90 HIV 
plan with the goal that 90% of HIV patients are diagnosed, 90% of HIV patients are 
treated with ART and 90% of HIV patients will achieve viral suppression (Levi et al, 
2016; Klatt, 2019; Wandeler et al, 2016; Heendeniya and Bogoch, 2019). While this goal 
is ideal for the world and for the HIV population, there is much to be done to attain this.  
 
 Compared to other ART drug classes, PIs are an optimal choice as they are well-
tolerated and have a high genetic barrier to resistance (Potempa et al 2015; Flexner, 2019; 
Klatt 2019; Sumner et al 2015). In addition, the development of LPV/r has reduced pill 
burden and cost of second-line therapies (See Table 3). It is already well known that 
lower pill burden increases compliance, which in turn will reduce the likelihood of drug 
resistance and transmission (Bangsberg et al, 2010; Buscher et al, 2012). However, as 
explained in this thesis, PIs increase the likelihood of CVD related deaths; in particular 
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LPV/r appears to have the highest associated risk (Squillace et al, 2018; Gleason et al, 
2015; Gleason et al, 2016; Longenecker et al, 2016; Hsue, 2019; Martin et al, 2006). 
However, more research is needed to ascertain why. It appears that there are potential 
mechanisms, as explained in the Potential Mechanisms subsection (pages 39 – 45) in the 
Protease Inhibitors, Cardiovascular Disease, and HIV (pages 38 – 49) section, but there 
isn’t enough evidence and research to fully understand them.  
 
 This thesis highlights the major gap in understanding PI-associated CVD. While 
dyslipidemia appears to be a strong risk factor, it is unknown what other risk factors there 
are. For many HIV patients, switching from first-line to second-line ART regimens is 
part of their treatment progression. Therefore, a large majority of the HIV population are 
now on PIs (Shroufi et al, 2019; Ayalew et al, 2016; Chimbetete et al, 2018; Haile and 
Berha, 2019). By understanding the mechanisms PIs pose to CVD, researchers can better 
evaluate and treat HIV patients by providing alternative therapies to manage CVD. In 
addition, researchers can create newer PIs with less of a CVD risk. While other PIs 
(SQV/r, ATV/r, DRV/r) have improved lipid profiles, there is much unknown about PIs 
and CVD to strongly suggest these as a safer alternative (Molina et al, 2010; Walmsley et 
al, 2009; Limsreng et al, 2016; Mills et al, 2009; Lai et al, 2003). 
 
 The newest class of IIs have proven to be a potential alternative to PIs. Multiple 
studies have shown DTG, RAL, and EVG improve lipid levels (Arribas et al, 2014; 
Taramasso et al, 2018; Martínez et al 2010; Martínez et al, 2012; Krikke et al, 2018; Eron 
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et al, 2010; Masiá et al, 2012; Negredo et al, 2016; Gatell et al, 2017). This is of 
particular importance as it has already been established that PIs increase the risk of 
dyslipidemia. However, due to the novelty of this drug class, there is little known about 
short and long-term side effects. Another major hurdle in switching from PIs to IIs is the 
financial burden of this drug class. As it is new, it is much costlier than other ART drugs. 
This financial burden can reduce adherence to ART and increase drug resistance 
(McAllister et al, 2013). This creates a quandary for HIV patients as they must choose 
between the latest, more expensive medications that may offer fewer side effects or 
cheaper and more cost-friendly ART regimens, but face the long-term side effects and 
drug toxicity.  
 
 In the fight against HIV/AIDS, medical providers and researchers have 
successfully completed the first step in managing HIV and increasing the life expectancy 
of infected patients. However, more needs to be done, and there is still much research 
needed. Now, the goal is to reduce drug toxicity, non-AIDS related conditions, and 
increase adherence and viral suppression. A step towards this goal is understanding the 




Table 1. AIDS Related Conditions. A comprehensive list of opportunistic infections 
that characterize the transition from Human Immunodeficiency Virus (HIV) to Acquired 




Table 2. FDA Approved HIV Medications. A timeline of when antiretroviral drugs 





Table 3. Cost of Protease Inhibitors and Integrase Inhibitors. A description of the 
wholesale acquisition cost (WAC), average wholesale price (AWP), and federal upper 


















Figure 1. Antiretroviral Therapy Targets. The current mechanisms by which each 
antiretroviral drug class targets. There are currently five drug classes: non-nuclocleoside 
reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase 





Figure 2. Factors Contributing to Non-AIDS related Conditions. The development 
of non-AIDs related conditions is complex and multi-factorial. Due to this, it is critical 
to understand how each play a factor in the development of various non-AIDs related 
conditions such as cardiovascular disease, bone disorders, and cognitive impairment. 




Figure 3. Reactive Oxygen Species Production. There are multiple ways in which 
reactive oxygen species are produced, which are not limited to metabolic reactions. 
However, dysregulation of these oxygen species can cause cellular damage. Glutathione 
reductase and peroxidase are mechanisms to prevent these oxygen species from causing 









Figure 4. Fenton Reaction/Haber-Weiss Reaction. A common way in which reactive 
oxygen species are formed are through hydrogen peroxide and iron. An increased 
production of hydrogen peroxide can cause an imbalance leading to a higher level of 







Figure 5. Antiretroviral Therapies and Dyslipidemia. Protease inhibitors are a primary 
culprit in the development of dyslipidemia in HIV patients. These can have varying 
alterations to lipid levels within the body. In particular, protease inhibitors have been 
shown to increase triglyceride levels and low-density lipoprotein levels. (Feeney and 







Figure 6. HIV Vaccine Clinical Trials. A timeline of clinical trials investigating HIV 
vaccines. While some were discontinued, due to ineffectiveness, RV144 showed 
potential. To date, there are multiple clinical trials investigating the development of an 
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